viewAnteris Technologies Ltd

Admedus reveals coronavirus mitigation strategy

The company is focused on continuing to manufacture clinical solutions for healthcare professionals.

Admedus Ltd - Admedus announces coronavirus mitigation strategy
The advisory board of physicians will meet via video conference

Admedus Ltd (ASX:AHZ) has confirmed that it will implement a Coronavirus mitigation strategy to limit the risk of an interruption to the continuity of supply and operations.

The company expects the impacts on operations to be minimal but will monitor the situation closely.

In the meantime, the company continues operating to plan and key projects are progressing as scheduled.

Manufacturing continues

The company is continuing to manufacture product for LeMaitre Vascular Inc (FRA:LHU).

LeMaitre’s feedback on its CardioCel® and VascuCel® patch sales remains positive with no downturn in customer orders at this stage.

Notably, the first-in-human 15 patient trial of the company’s ADAPT® single-piece 3D aortic valve for surgical aortic valve replacement at the Universities’ Hospital, Leuven (Belgium) remains on track to proceed as scheduled with the first patient expected to undergo surgery by month’s end.

However, disruption due to COVID-19 demands on hospital resources may delay this into April 2020.

Some disruptions expected

The chief disruption to date is to corporate and medical conferences due to event cancellations and travel restrictions.

The company’s advisory board of physicians continues to meet and will hold its next meeting via video conference next week.

Measures implemented

Key additional measures have implemented as part of the company’s coronavirus mitigation strategy and effect:

  • travel policy,
  • personnel practices, and
  • manufacturing continuity.

Excluding manufacturing and research and development, staff and contractors will work from home during the pandemic.

Quick facts: Anteris Technologies Ltd

Price: 3.61 AUD

Market: ASX
Market Cap: $21.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...



Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

on 6/7/20

2 min read